Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis
Susan Yount*, Mark V. Sorensen, David Cella, Nishan Sengupta, James Grober, Elliot K. Chartash
Dive into the research topics of 'Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis'. Together they form a unique fingerprint.